Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antibody Actions01:26

Antibody Actions

1.1K
Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
1.1K
Enzyme-Linked Immunosorbent Assay01:33

Enzyme-Linked Immunosorbent Assay

12.9K
In 1971, Peter Perlman and Eva Engvall developed an Enzyme-linked immunosorbent assay (ELISA or EIA). ELISA differs from western blot in that the assays are conducted in microtiter plates or in vivo rather than on an absorbent membrane.
There are many different types of ELISAs, but they all involve an antibody molecule whose constant region binds an enzyme, leaving the variable region free to bind its specific antigen.  Enzyme-substrate reaction allows the antigen to be visualized or...
12.9K
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

7.1K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
7.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antiphospholipid syndrome (APS) is a platelet factor 4 (PF4)-centric immunothrombotic disorder.

Blood·2026
Same author

A call to action for the use of composite hematologic measurements in hereditary hemorrhagic telangiectasia and other chronic bleeding disorders.

Expert review of hematology·2026
Same author

Correction: PIGN spatiotemporally regulates the spindle assembly checkpoint proteins in leukemia transformation and progression.

Scientific reports·2026
Same author

Noninvasive Monitoring of Complement Using the Bioluminescent Modified Ham Assay in the Second Porcine-to-Human Live Heart Transplant.

Xenotransplantation·2026
Same author

Bradykinin Contributes to Vasogenic Edema in Murine Experimental Cerebral Malaria.

bioRxiv : the preprint server for biology·2026
Same author

Defining "Dominance" in Atypical Hemolytic Uremic Syndrome: Distinguishing Amplification From Initiation.

Kidney international reports·2026

Related Experiment Video

Updated: Jun 24, 2025

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells
06:29

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells

Published on: January 29, 2014

30.6K

Complement Biosensors Identify a Classical Pathway Stimulus in Complement-Mediated Hemolytic Uremic Syndrome.

Michael A Cole, Nikhil Ranjan, Gloria F Gerber

    Biorxiv : the Preprint Server for Biology
    |June 10, 2024
    PubMed
    Summary
    This summary is machine-generated.

    Complement-mediated hemolytic uremic syndrome (CM-HUS) diagnosis is improved with novel cell-based biosensors. These tools identify an IgM-driven stimulus, explaining CM-HUS cases lacking alternative pathway variants.

    More Related Videos

    Measuring the 50% Haemolytic Complement CH50 Activity of Serum
    08:26

    Measuring the 50% Haemolytic Complement CH50 Activity of Serum

    Published on: March 29, 2010

    37.8K
    Measuring Erythrocyte Complement Receptor 1 Using Flow Cytometry
    07:20

    Measuring Erythrocyte Complement Receptor 1 Using Flow Cytometry

    Published on: May 19, 2020

    7.2K

    Related Experiment Videos

    Last Updated: Jun 24, 2025

    Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells
    06:29

    Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells

    Published on: January 29, 2014

    30.6K
    Measuring the 50% Haemolytic Complement CH50 Activity of Serum
    08:26

    Measuring the 50% Haemolytic Complement CH50 Activity of Serum

    Published on: March 29, 2010

    37.8K
    Measuring Erythrocyte Complement Receptor 1 Using Flow Cytometry
    07:20

    Measuring Erythrocyte Complement Receptor 1 Using Flow Cytometry

    Published on: May 19, 2020

    7.2K

    Area of Science:

    • Immunology
    • Hematology
    • Biotechnology

    Background:

    • Complement-mediated hemolytic uremic syndrome (CM-HUS) is a serious thrombotic microangiopathy.
    • Diagnosis often relies on identifying genetic variants or antibodies affecting complement regulation.
    • Existing diagnostic methods may not fully explain all CM-HUS cases.

    Purpose of the Study:

    • To develop and validate novel cell-based complement biosensors for CM-HUS diagnosis.
    • To investigate the role of complement pathways, particularly IgM-driven stimuli, in CM-HUS pathogenesis.
    • To assess the utility of these biosensors in monitoring complement inhibitor therapies.

    Main Methods:

    • Engineered HEK293 cells lacking specific complement regulatory proteins (CD55, CD59, CD46) to create bioluminescent biosensors.
    • Utilized a modified Ham (mHam) assay framework for ex vivo complement analysis.
    • Employed specific complement pathway inhibitors to dissect pathway activation.

    Main Results:

    • The developed biosensors effectively diagnose CM-HUS and monitor complement blockade.
    • Identified an IgM-driven classical pathway stimulus in CM-HUS patients, even during remission.
    • This finding potentially explains ~50% of CM-HUS cases without alternative pathway variants.

    Conclusions:

    • Cell-based complement biosensors offer a sensitive diagnostic tool for CM-HUS.
    • A subset of CM-HUS may result from a breakdown of IgM immunologic tolerance.
    • These biosensors can aid in diagnosing CM-HUS and guiding complement inhibitor treatment.